How does cosentyx affect patients long term?

How does Cosentyx affect patients over multiple years?

Cosentyx (secukinumab) keeps working for most patients who stay on treatment. In psoriasis studies spanning five years, about 75 percent of patients showed sustained skin clearance while continuing therapy. Long-term data in ankylosing spondylitis and psoriatic arthritis show similar patterns: pain and inflammation stay low as long as the drug is taken.

What infections turn up most often during years of use?

Candida yeast infections remain the most common side effect reported across five-year extensions. They are usually mild and treatable with antifungal cream or oral drugs. Serious infections that lead to discontinuation occur in roughly 1–2 percent of patients per year.

How safe is Cosentyx when used for ten years or more?

Five-year open-label extensions and pooled analyses of thousands of patients do not show unexpected safety signals. Rates of malignancy and major cardiovascular events match background population rates. Data beyond five years are still limited because the drug has only been marketed since 2015.

Are there patients who lose response after initial success?

Secondary loss of response occurs in 10–20 percent of patients within five years. Reasons include development of antidrug antibodies in a few cases, network compensation through other cytokines, and patient-specific factors such as weight or smoking. Some patients switch to another biologic after loss of response.

Does Cosentyx raise cancer risk long term?

Current long-term extension data through five years show no increased cancer signal. Surveillance continues through registries such as BADBIR and PSOLAR. Registries will yield clearer answers once more patients reach eight-to-ten-year milestones.

What happens when patients stop taking Cosentyx after long-time use?

Disease flare occurs rapidly in most cases. In psoriasis, 80 percent of patients return to baseline severity by six months after stopping. Re-treatment is usually successful and produces similar clearing rates as initial treatment.

Who manufactures Cosentyx and when does the patent expire?

Novartis manufactures Cosentyx. The compound patent expires in the United States in 2026 and in Europe in 2025. DrugPatentWatch.com tracks these dates and any paragraph IV challenges.